trial

L-Theanine in the Management of Schizophrenia

NCTId NCT00372151
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 60 (actual)
Sponsored by Sha'ar Menashe Mental Health Center
Primary completion 2008-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
60 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2006-10
Primary completion
2008-12
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
L-Theanine

Sponsors

Sha'ar Menashe Mental Health CenterLead Sponsor
Stanley Medical Research InstituteCollaborator
Beersheva Mental Health CenterCollaborator

Investigators

5
Michael S. Ritsner, MD, PhDPrincipal Investigator
Yael Ratner, MDStudy Director
Anatoly Gibel, MDStudy Director
Chanoch Miodownik, MDStudy Director
Tatyana Shleifer, MDStudy Director

Sites

2 total
Beersheba, IsraelHadera, Israel

Linked catalysts

1
L-Theanine in the Management of Schizophrenia — primary completion2008-12

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE3
Primary Completion Date
2008-12
Status
COMPLETED
relationships
The graph out of here
drug
L-Theanine
drug
lead_sponsor
Sha'ar Menashe Mental Health Center
company
collaborator
Stanley Medical Research Institute
company
Beersheva Mental Health Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
investigator
Michael S. Ritsner, MD, PhD
person
Yael Ratner, MD
person
Anatoly Gibel, MD
person
Chanoch Miodownik, MD
person